Investment Pillar: Healthcare
Venture Equity Financing for Advancing Healthcare Companies
Healthcare investment is part of our DNA here at OneVentures. Our first fund, our first investment, our first exit and our first investor returns came from OneVentures’ Partners wanting to improve the quality of life of people around the world, while generating strong returns for our investors. Now, we have even stronger ambitions to accelerate the healthcare companies of tomorrow.
We are interested in transformative technology that will deliver best-in-class patient outcomes with global reach and impact.
Healthcare Investment Cases
OneVentures have been terrific to work with as a lead investor, but it’s what they add in addition to investment that has been critical to Vaxxas’ growth.
Their biotech team comes from leadership roles with hands-on industry experience spanning technology to business development. Vaxxas is tremendously fortunate – working with the OneVentures team has translated into sharpening all aspects of our development and commercialisation strategy, and actively helped us forge connections and partners with industry. I cannot recommend them highly enough.
OneVentures are a unique, one of a kind investor in the venture capital world.
They put tremendous faith in their portfolio company’s teams to deliver results, and are always on hand to provide pointed advice or step in to fill organisational gaps. BiVACOR has fortunately been part of the OneVentures family for nearly 4 years now, and their unyielding support has allowed our organisation to pursue our dream of developing a practical replacement to the failing human heart. Without the OneVentures team, we would not be where we are today!
CEO, Blade Therapeutics
I first met the OneVentures team in July 2018. They quickly impressed me with their broad knowledge and capabilities.
Shortly afterwards, they led Blade Therapeutics‘ Series C round. It has been a pleasure to build the company with the support of Paul, Sarah, Michelle, and Gabriel, and their LP’s over the past 3 years. The fund is a true value add investor with deep connections to academic institutions and opinion leaders.
Healthcare Investment Team
Dr Paul Kelly
Founding Partner & Director
| MBBS(Hons), MD, FRACP | Location: Sydney, AU
Dr Paul Kelly is Founding Partner & Director at OneVentures. Starting with his background as an Australian Physician, Paul has a long history of biotechnology entrepreneurship and healthcare investing, from developing innovation to commercialising at scale and realising substantial returns for investors.
Having returned to Australia in 2010 (after 15 years in the UK and US), he is dedicated to improving healthcare and treatment options for populations across the world. He lives and invests guided by his vision for a better future: through innovation, collaboration, and patient determination.
Paul is an avid reader and can regularly be found immersed in medical journals as well as fiction and non-fiction literature, which he believes “provides perspectives and insights that you would never get from management or business books”.
When he’s not mentoring and encouraging medical professionals to be entrepreneurial, he also looks after the health of our native environment: being highly active in bush regeneration and preservation.
Paul serves on the investment committees of OneVentures’ four main Funds, chairing the Fund III Investment Committee, and leading the healthcare and biotechnology practice across the firm.
Paul is a highly experienced executive and has multiple board responsibilities as either Chair or as a Non-Executive Director within numerous OneVentures portfolio companies. Independently of OneVentures, he is also a Non-Executive Director Garvan Institute of Medical Research
Paul has over 30 years’ experience in developing and commercialising biomedical innovations in the United States, Europe, United Kingdom and Australia. While in the UK and US he led early-stage and mid-stage companies, public and private, delivering strong returns for shareholders and investors as a founder and CEO.
Notably, Paul served as Co-Founder and CEO of Gemini Genomics (Nasdaq:GMNI), one of the world’s first clinical genomics companies, commercialising novel gene-based diagnostic and therapeutic targets. At Gemini, Paul led the company in one of the UK’s largest biotechnology IPOs of the time, completed strategic corporate acquisitions in Sweden and Canada, and negotiated collaborations with some of the world’s leading research institutions and biotechnology and pharmaceutical companies. In 2001, Paul led the company’s successful merger with Sequenom (Nasdaq:SQNM), valuing Gemini at over US$250M.
Paul’s other notable achievements include co-founding Agamatrix, now a leading bio-sensing medical device company with operations across the US and South East Asia, and Atomera (Nasdaq ATMR). He then served as President and CEO of Orchid Cellmark (Nasdaq:ORCH) – during his tenure revenues grew by over 50% in 2 years to $60M per annum, and increased the company valuation 10 fold.
While in the US Paul also served as President and CEO of Medcenter Solutions, a US based online medical education and pharmaceutical marketing company.
Before becoming a biotechnology executive, Paul had a distinguished career as a researcher and physician specialising in endocrinology at St Vincent’s Hospital, Sydney, Australia. While serving as a researcher at the Garvan Institute of Medical Research in Sydney, and in his postdoctoral work, Paul authored over 100 scientific publications, largely in genetic epidemiology of common metabolic disorders, which have been published in leading journals such as Nature, New England Journal of Medicine, The Lancet, British Medical Journal and Proceedings of the National Academy of Science.
Paul has also served on a number of national governmental advisory bodies, as well as on the boards of public and private companies. He served on the Board of Directors of the American Society of Medicine, Law and Ethics from 2005 to 2008. He also serves on the UNSW Medicine Dean’s Advisory Group and serves on the Board of Directors of the Garvan Institute of Medical Research.
Portfolio Board Roles
In the news
07 October 2021
Blade Therapeutics Announces Publication of Preclinical Evidence Supporting Neuroprotective Effects of Proprietary Calpain Inhibitor in a Rare Inherited Neurodegenerative Disease
02 June 2021
Preclinical studies from Vaxxas and Collaborators Reveal Potential of Vaxxas’ Novel High-Density Microarray Patch (HD-MAP) to Effectively Deliver SARS-CoV-2 Spike Vaccine
Co-Founder, Venture Partner & Director
| BSc(Hons), MBA, GAICD | Location: Brisbane, AU
Anne-Marie Birkill is a Co-Founder, Venture Partner, and Director of the Manager at OneVentures. She is well regarded for her passion for and experience of working with early-stage technology companies and entrepreneurs including as an expert advisor within the innovation community. She is based in Brisbane, a strong source of technology innovation opportunities.
Anne-Marie serves on the investment committees of OneVentures’ Funds I, II and III and the REM and Risk Management Committees. She is a director for OneVentures portfolio company Madorra and was Chair of the Board of Charm Health until 2017 when she lead the company to an acquisition by the Citadel Group (ASX:CGL). She originated Vaxxas in 2010 and was an observer to the Vaxxas Board until 2020.
Driven by a passion to grow Australia’s knowledge-based economy; Anne-Marie brings 35+ years’ experience in executive leadership, product development and commercialisation, advisory roles, mentorship, capital raising and exits to the team at OneVentures. Her interest in the innovation sector was forged during 15 years in leadership roles in agri-business companies developing and commercialising new cultivars of ornamental, aquatic, food, and forestry plants. Prior to co-founding OneVentures in 2010, she was CEO of i.lab Incubator, having previously spent five years in the senior management team at UniQuest. During this period Anne-Marie developed successful programs and networks to assist technology commercialisation, start-up formation and growth, capital raising and exit. She has experience of senior management and governance in listed and unlisted companies.
A committed advocate for diversity, equity and inclusion, Anne-Marie regularly contributes to thought leadership on this topic including via speaking engagements. For media and speaking enquiries, please contact us.
Her experience and reputation in the technology sector is demonstrated through her active participation in the innovation community. Her current external roles include appointment as an Industry Fellow with The University of Queensland (UQ) Business School, Chair of the Investment Committee for the UQ-lead “Trailblazer” Food and Beverage Accelerator, and director for InterFinancial Corporate Finance and the PPK Group (ASX:PPK).
Portfolio Board Roles
In the news
13 August 2018
OneVentures invests in regional Queensland company developing treatments for autoimmune diseases
| BAgrSc(Hons), M.P.S, GAICD | Location: Brisbane, AU
Sarah is responsible for sourcing life sciences companies and actively shaping their future. She applies her global executional experience and entrepreneurial passion to nurture their success. Her enterprise level leadership experience has been forged over 20 years in a wide spectrum of organisations, including start-up, private companies, ASX and NASDAQ-listed companies, a multi-national pharmaceutical company and university research organisations.
Prior to OneVentures, she was the Asian Business Development lead for Shire Pharmaceuticals (now Takeda), a global specialty pharmaceutical company. Sarah identified technologies and developed collaborations across Japan, Korea, Australia, New Zealand, Singapore and Taiwan including playing a key role in sourcing the $300M Fibrotech deal announced in 2015.
Sarah has held senior management roles at Progen Pharmaceuticals, The University of Queensland’s QAAFI institute, Beef CRC and Pyxis Genomics. From 2011-2017 she led the development of the new UQ QAAFI research institute from 32 people to 450 people and a financially profitable position within 5 years. This included leading the negotiation of a complex $70+M staff transfer and research agreement for QAAFI between the University of Queensland and the Queensland Government. In 2012, Sarah spearheaded the IP asset assignment and company wind-up of 20 year $168M Beef Co-operative Research Centre, involving five universities across five state jurisdictions, MLA, CSIRO and Meat and Lamb NZ and pastoral companies. At Progen Pharmaceuticals, Sarah worked collaboratively with the CEO and CFO over several years to secure a total financing of ~$125M via five capital raisings for oncology drug development, and in 2008 led the $22M acquisition of an oncology drug discovery company.
Sarah has a strong understanding of the pharmaceutical, medical device and healthcare industries including key inflexion points, intellectual property, regulatory and reimbursement strategies, business development options and strategic product management. She combines this with the ability to understand scientific information quickly and build credibility with technical experts and industry players. She is passionate about commercialising new technologies, and has the strategic vision and positive energy to deliver under tight timeframes in a team environment.
Sarah is a graduate of the Australian Institute of Company Directors (GAICD) and currently holds directorships with Kira Biotech, QAAFI Advisory Board and Life Sciences Queensland. She holds Bachelor level science qualifications from the University of Queensland and a Masters from Cornell University and has completed a postgraduate course at Harvard Business School focusing on negotiation and decision making.
Dr Jeannie Joughin
| BSc(Hons), PhD | Location: Melbourne, AU
Jeannie is an experienced biopharmaceutical and medical device leader with 20+ years’ experience locally and internationally. She is responsible for sourcing and supporting biotech, device and diagnostics companies to achieve future success. Having held senior executive level positions globally, she brings extensive expertise in business development transactions, strategic partnerships and alliance management to support investment strategy. Her operational and leadership experience in research, clinical trial and commercial management has been forged through conducting research at universities, holding positions of increasing seniority in multi-national pharmaceutical companies and from start-up environments in private and listed companies located in the USA, Europe and Australia.
Prior to OneVentures, Jeannie held senior executive and advisor positions in Australia and currently serves as a director for Paranta Biosciences. While in the US she was responsible for global business development activities and successfully licensed a medical device technology to several of the world’s largest pharmaceutical companies attracting sizable milestone and royalty payments. She has demonstrated commercial success and operational expertise by building businesses and brands in several therapeutic areas in different geographies. She has a global perspective with strong analytical, regulatory and technical skills, and is passionate about working with and developing teams to support execution of corporate, product and business strategy. This experience has come from working in companies in Australia and the USA including Bristol-Myers Squibb, Mayne Pharma, CSL and CSL Behring, Enable Injections Inc., Paradigm Biopharmaceuticals, Glutagen and Paranta Biosciences.
Dr Joughin holds a PhD and a Bachelor of Science (Hons) in Immunology from Monash University in Melbourne and a Diploma of Marketing from the Melbourne Business School.
Dr Lu Li
| PhD, Pathobiology | Location: Sydney, AU
Dr Lu Li is an investment analyst in OneVentures’ Healthcare team.
Lu supports the Healthcare team by performing quantitative and qualitative research to inform investment, valuation and exit decisions. Lu also assists with deal screening and performing due diligence whilst also reporting and monitoring existing and prospective fund investments.
Lu regularly practices meditation and loves to study herbal medicine. She also paints and sketches in her free time.
Lu brings over 7 years of biomedical research experience in academia to the OneVentures team. She has a strong technical background on research & development in general, and always follows the latest research progress.
In addition, Lu brings her depth of experience for financial modelling and equity research, along with her keen interest in finance.
Prior to joining with OneVentures, Lu joined CITIC’s Biotech Equity Research area as an intern. She later worked as a scientific writer and technical consultant at DeepTech, a new media platform, where she covers biotech startups and latest biomedical research, and simultaneously completed level 2 of the CFA.
Lu received her Ph.D in Pathobiology from the University of Connecticut in the US, where she focused her research on infectious disease pathogenesis.
Criteria for Entrepreneurs
To fit our mandate, your company must be:
- Developing products or technologies that are first or best in class
- Innovative solutions that meet a large unmet medical need
- Clinical stage or less than a year from first in-human studies
- Privately owned and unlisted
Healthcare Fund III
We invest in entrepeneurs and technologies that have the potential transform healthcare and health outcomes globally with a focus on therapeutics, devices and diagnostics at or near clinical development. Our healthcare team look to partner with founders and CEOs who have a clear commercial, regulatory and reimbursement pathway, who have strong ESG principles as a foundation of their business.
Licenced under the Commonwealth Government’s Biomedical Translation Fund (BTF) programme, the fund targets investments of $10 to $20 million per company in Australian domiciled companies. The OneVentures team provides support to drive these opportunities through the clinical, regulatory and reimbursement processes to achieve prominence in global markets.
Experience in the field
The OneVentures healthcare team has a strong history of biomedical entrepreneurship, with experience commercialising biomedical innovation across the United States, Europe, United Kingdom and Australia.
Partnering with portfolio companies
OneVentures’ investing strategy focuses on investing to milestones – to ensure we are only partnering with those companies that are performing and achieving key validation steps. We look towards proof of clinical efficacy and safety, backed by quality science with a clear regulatory and reimbursement path.
Investing in people, science and operations
The OneVentures team have a hands on approach with our investments, and believe in the quality of people and relationships to deliver long term success. With a history of achievement in transforming ideas, technologies and products into successful businesses, our collaborative approach looks to deliver successful outcomes for all our stakeholders.
Innovation & Growth Fund II
The capital for this Fund has been fully deployed.
The Fund invested in early and later stage technology and healthcare companies seeking growth and development capital including for offshore expansion – particularly those with a strong product market fit and a clear path to revenue.
Innovation Fund I
The capital for this fund has been fully deployed.
Backed by the Commonwealth Government’s Innovation Investment Fund programme, the fund invested in early-stage Seed and Series A technology and healthcare companies.
A pathway to partnership.
Do you believe your company is a good fit to our investment mandate?
Our preference is for a warm introduction to be made through our network. You may know someone we’ve worked with before, otherwise the team is active at industry events – so come and say hello!
If this is not possible, please submit an application.
BROADENING THE SCOPE OF IMPACT
There are many different types of companies, so we provide many different solutions for raising capital.
We believe that the world’s most transformative companies will be those that benefit society.
That’s why we apply a Responsible Investment filter to all prospective portfolio companies, especially seeking those that demonstrate strong ESG principles.
Clinical Healthcare Investment
"*" indicates required fields